Dermatologic Adverse Effects of Lenalidomide Therapy for Amyloidosis and Multiple Myeloma
Open Access
- 1 October 2006
- journal article
- research article
- Published by American Medical Association (AMA) in Archives of Dermatology
- Vol. 142 (10) , 1298-1302
- https://doi.org/10.1001/archderm.142.10.1298
Abstract
Lenalidomide is an oral bioavailable analogue of thalidomide belonging to a class of immunomodulatory drugs. Compared with thalidomide, it has been reported to have more potent immunomodulatory, antiangiogenic, and antitumor activities and a better safety profile.1Keywords
This publication has 15 references indexed in Scilit:
- Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myelomaBlood, 2005
- Emerging Data on IMiDs in the Treatment of Myelodysplastic Syndromes (MDS)Seminars in Oncology, 2005
- The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL)Blood, 2005
- Immunomodulatory Analogs of Thalidomide: An Emerging New Therapy in MyelomaJournal of Clinical Oncology, 2004
- High-Dose Melphalan and Autologous Stem-Cell Transplantation in Patients with AL Amyloidosis: An 8-Year StudyAnnals of Internal Medicine, 2004
- Therapy for immunoglobulin light chain amyloidosis: the new and the oldBlood Reviews, 2003
- Tolerability and Efficacy of Thalidomide for the Treatment of Patients with Light Chain–Associated (AL) AmyloidosisClinical Lymphoma, 2003
- Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosisAmyloid, 2003
- Autologous stem cell transplantation for primary systemic amyloidosisBlood, 2002
- A modified high‐dose dexamethasone regimen for primary systemic (AL) amyloidosisBritish Journal of Haematology, 2001